Lothian NHS Board

NHS Lothian Headquarters
Waverley Court
4 East Market Street
Edinburgh
EH8 8BG
www.nhslothian.scot

Date 20 October 2026
Your Ref
Our Ref 11941

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to prescribing.

Question:

1. How many patients received treatment for any condition in the last six months with any of the following treatment regimens (March 2026 – August 2026)?
   - Ocrevus (ocrelizumab) IV
   - Ocrevus (ocrelizumab) Subcutaneous
   - Kesimpta (ofatumumab)
   - Briumvi (ublituximab)
   - Mavenclad (cladribine)
   - Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
   - Vumerity (diroximel fumarate)
   - Tysabri (natalizumab) IV
   - Tysabri (natalizumab) Subcutaneous
   - Tyruko (natalizumab biosimilar)
   - Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids)
   - S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)

Answer:

March 2026 - August 2026 Medication	Patient Count
Ocrevus (ocrelizumab)	Information Unavailable
Kesimpta (ofatumumab)	257
Briumvi (ublituximab)	Information Unavailable
Mavenclad (cladribine)	5<
Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	321
Vumerity (diroximel fumarate)	43
Tysabri (natalizumab)	Information Unavailable
Tyruko (natalizumab biosimilar)	0
Any Other Platform Therapies (interferon Beta, peginterferon	103

beta-1a, teriflunomide, glatiramoids)	
S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)	125

Question:

2. Of the patients identified in question one, how many of the same patients received treatment with each treatment regimen in November 2025-April 2026 AND March 2026 – August 2026)?
   - Ocrevus (ocrelizumab) IV
   - Ocrevus (ocrelizumab) Subcutaneous
   - Kesimpta (ofatumumab)
   - Briumvi (ublituximab)
   - Mavenclad (cladribine)
   - Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
   - Vumerity (diroximel fumarate)
   - Tysabri (natalizumab) IV
   - Tysabri (natalizumab) Subcutaneous
   - Tyruko (natalizumab biosimilar)
   - Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids)
   - S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)

Answer:

For patients treated with the specified medicines within NHS Lothian services between March 2026 and August 2026, the table below shows the number of patients who were also treated with the specified medicines during the preceding six-month period (November 2025 to April 2026).

Medication	Patient Count
Ocrevus (ocrelizumab)	Information Unavailable
Kesimpta (ofatumumab)	236
Briumvi (ublituximab)	Information Unavailable
Mavenclad (cladribine)	5<
Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	308
Vumerity (diroximel fumarate)	34
Tysabri (natalizumab)	Information Unavailable
Tyruko (natalizumab biosimilar)	0
Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids)	99
S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)	121

Question:

3. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (March 2026 – August 2026)?

Answer:

Approximately 73 patients in NHS Lothian have been diagnosed with MS between 01/03/2026 and 31/08/2026

Question:

4. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?
   - Ocrevus (ocrelizumab) IV
   - Ocrevus (ocrelizumab) Subcutaneous
   - Kesimpta (ofatumumab)
   - Briumvi (ublituximab)
   - Mavenclad (cladribine)
   - Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
   - Vumerity (diroximel fumarate)
   - Tysabri (natalizumab) IV
   - Tysabri (natalizumab) Subcutaneous
   - Tyruko (natalizumab biosimilar)
   - Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids)
   - S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)

Answer:

Ocrevus (ocrelizumab) IV	5<
Ocrevus (ocrelizumab) Subcutaneous	5<
Kesimpta (ofatumumab)	14
Briumvi (ublituximab)	12
Mavenclad (cladribine)	5<
Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	9
Vumerity (diroximel fumarate)	5<
Tysabri (natalizumab) IV	5<
Tysabri (natalizumab) Subcutaneous	5<
Tyruko (natalizumab biosimilar)	5<
Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids)	5<
S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)	5<

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: https://org.nhslothian.scot/FOI/Pages/default.aspx

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive